Effect of BBT-877, a novel inhibitor of ATX, on a mouse model of type 1 diabetic nephropathy
Open Access
- 26 August 2022
- journal article
- research article
- Published by Impact Journals, LLC in Aging
- Vol. 14 (16) , 6467-6480
Abstract
Diabetic nephropathy (DN) is one of the common microvascular complications of diabetes. Autotaxin (ATX) is an enzyme with lysophospholipase D activity, producing lysophosphatidic acid (LPA). LPA signaling has been implicated in renal fibrosis, thereby inducing renal dysfunction. BBT-877 is an orally administered small molecule inhibitor of ATX. However, its effect on DN has not been studied so far. In this study, we investigated the effect of BBT-877, a novel inhibitor of ATX, on the pathogenesis of DN in a mouse model of streptozotocin (STZ)-induced diabetes. BBT-877 treatment significantly reduced albuminuria, albumin-to-creatinine ratio (ACR), neutrophil gelatinase-associated lipocalin (NGAL), and glomerular volume compared to the STZ-vehicle group. Interestingly, BBT-877 treatment attenuated hyperglycemia and dyslipidemia in STZ-induced diabetes mice. In the liver, the expression levels of β-oxidation-related genes such as PPAR α and CPT1 were significantly decreased in STZ-induced diabetic mice. However, this effect was reversed by BBT-877 treatment. BBT-877 treatment also suppressed mRNA levels of pro-inflammatory cytokines IL-6, MCP-1, and TNF-α and protein levels of fibrotic factors (TGF-β, fibronectin, CTGF, and collagen type Ι alpha Ι (COL1A1)) in the kidneys of STZ-induced diabetic mice. In conclusion, our results indicate that BBT-877 is effective in preventing the pathogenesis of DN by reducing systemic blood glucose levels and inhibiting inflammation and fibrosis in the renal tissue of diabetes mice. These novel findings suggest that inhibition of ATX may be a potential therapeutic target for DN.Keywords
This publication has 44 references indexed in Scilit:
- Mechanistic connection between inflammation and fibrosisKidney International, 2010
- The Role of Toll-Like Receptor 2 in Inflammation and Fibrosis during Progressive Renal InjuryPLOS ONE, 2009
- Lysophosphatidic acid and renal fibrosisBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2008
- Autotaxin, a Secreted Lysophospholipase D, Is Essential for Blood Vessel Formation during DevelopmentMolecular and Cellular Biology, 2006
- Renal Protection in DiabetesJournal of the American Society of Nephrology, 2006
- Role of anti-TGF-β antibodies in the treatment of renal injuryCytokine & Growth Factor Reviews, 2006
- Renal fibrosis: New insights into the pathogenesis and therapeuticsKidney International, 2006
- New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathologyEuropean Journal of Clinical Investigation, 2004
- Autotaxin Is Released from Adipocytes, Catalyzes Lysophosphatidic Acid Synthesis, and Activates Preadipocyte ProliferationJournal of Biological Chemistry, 2003
- Effects of Losartan on Insulin Sensitivity in Hypertensive SubjectsHypertension, 1996